Indications：
Abemaciclib is a kinase inhibitor indicated for:
- In combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence.
- In combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.
- In combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer who have progressed after endocrine therapy.
- As monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer who have progressed after endocrine therapy and prior chemotherapy in the metastatic setting.
Dosage and Administration：
Abemaciclib tablets may be taken with or without food.
- When used in combination with fulvestrant, tamoxifen, or an aromatase inhibitor:
Recommended starting dose is 150 mg orally twice daily. - When used as monotherapy:
Recommended starting dose is 200 mg orally twice daily. - Dose interruptions and/or dose reductions may be required based on individual safety and tolerability.
Specification
50 mg per tablet, 56 tablets per box.
Reviews
There are no reviews yet.